Benefits
Cholesterol reduction in elderly hypercholesterolemia
An RCT tested 860 mg/day squalene over 20 weeks in elderly patients with primary hypercholesterolemia, finding significant reductions vs placebo in total cholesterol and LDL-C, plus modest TG reduction (-5.3%) and HDL increase (+1.8%). Well-tolerated with infrequent minor side effects. The strongest cardiovascular evidence, though replication has been mixed (some studies show no effect or even modest TC elevation at higher doses).
Skin barrier protection and emollient (topical squalene/squalane)
Squalene comprises ~12% of human skin surface lipids and is a major component of sebum. Topical application restores barrier function in stripped/SLS-damaged skin, reversing elevated transepidermal water loss and riboflavin penetration. Sebum squalene also functions as a singlet-oxygen quencher protecting skin from UV-induced lipid peroxidation. Squalane (hydrogenated form) is widely used in cosmetic emollients.
Antioxidant/singlet oxygen quenching (mechanistic)
Squalene quenches singlet oxygen efficiently and is highly resistant to peroxidation itself, making it an effective protective lipid in tissues exposed to oxidative stress (especially skin). Mechanistic basis for the cosmetic dermatology applications — protects unsaturated membrane lipids from peroxidation chains in vivo.
Vaccine adjuvant (MF59®, AS03 — established clinical use)
Squalene-in-water emulsion adjuvants (MF59 in influenza vaccines, AS03 in pandemic H1N1) significantly enhance immunogenicity of inactivated antigens. Well-established efficacy and safety in millions of doses globally; Fluad has been licensed since 1997 in Europe and is now FDA-approved. This is the strongest clinical use case for squalene, though distinct from oral supplementation.
Mechanism of action
Singlet oxygen quenching and resistance to peroxidation
Squalene's six conjugated double bonds make it an efficient quencher of singlet oxygen (¹O₂) — particularly relevant in skin where UV exposure generates ROS. Unlike polyunsaturated fatty acids, squalene resists peroxidation chain reactions, allowing sustained protection. Skin sebum squalene oxidation produces 'squalene peroxide' which is implicated in acne pathology — a counterbalancing pro-inflammatory effect.
Cholesterol biosynthesis intermediate (HMG-CoA reductase pathway)
Squalene is the first 30-carbon intermediate in the cholesterol biosynthesis pathway, formed by squalene synthase from two farnesyl pyrophosphate molecules and converted to lanosterol by squalene monooxygenase. Dietary squalene partially substitutes for endogenous synthesis, potentially down-regulating HMG-CoA reductase activity — the speculative mechanism for cholesterol-lowering effects, though competitive feedback with endogenous synthesis explains the inconsistent outcomes.
Lipoprotein 'sink' for lipophilic xenobiotics
As a non-polar hydrocarbon distributed in VLDL and LDL, squalene may serve as a 'sink' for lipophilic xenobiotics, sequestering them and modulating their bioavailability. Theoretical mechanism for hepatoprotective and antitoxicant effects observed in animal studies.
Immune stimulation (oil-in-water emulsion delivery)
Squalene-in-water emulsions activate the innate immune response at the injection site, recruiting antigen-presenting cells and enhancing antigen uptake. Importantly, squalene itself is not 'recognized' as foreign — natural antibodies to squalene are present in many individuals at low titer with no clinical significance. The adjuvant effect derives from the emulsion physical properties plus mild local irritation.
Clinical trials
Randomized double-blind placebo-controlled trial (Chan P, Tomlinson B, Lee CB, Lee YS 1996, J Clin Pharmacol 36(5):422-427).
102 elderly patients with primary hypercholesterolemia. Randomized to 860 mg/day squalene, low-dose pravastatin, combination, or placebo for 20 weeks.
Squalene 860 mg/day significantly reduced total cholesterol and LDL-C vs placebo. Modest TG reduction (-5.3%) and HDL increase (+1.8%). Well-tolerated with minor and infrequent side effects. Combination with pravastatin produced additive effects. The clearest positive cardiovascular trial of squalene supplementation. Foundational evidence for the 500-860 mg/day dose range in subsequent recommendations.
Comparative metabolic study (Strandberg TE, Tilvis RS, Miettinen TA 1990, J Lipid Res 31(9):1637-1643).
Patients with cerebrovascular and cardiovascular disease plus hypercholesterolemia. 900 mg/day squalene for 30 days, with comparison to cholestyramine.
Inconsistent elevation of free and esterified cholesterol in patient serum during squalene feeding — suggesting upregulation of cholesterol synthesis by squalene at this dose. The inverse of expected effects. Importantly, this study demonstrated that high-dose squalene can elevate cholesterol synthesis as measured by serum non-cholesterol sterol surrogates. Helps explain conflicting results: 500-860 mg/day seems to lower cholesterol in some populations while ≥900 mg/day may elevate synthesis markers.
Postprandial pharmacokinetic study (Relas H, Gylling H, Miettinen TA 2000, Atherosclerosis 152(2):507-518).
16 male volunteers aged 22-79 years receiving two oral fat meals one week apart — one without squalene and one with 500 mg squalene.
Squalene from a single oral 500 mg dose was detectable in plasma within hours, transported in fasting samples mainly via LDL and HDL but immediately postprandially via triglyceride-rich lipoproteins (chylomicrons, VLDL). Cholesterol synthesis (measured by non-cholesterol sterol surrogates) increased acutely after the dose — confirming that exogenous squalene drives endogenous synthesis pathway flux. Foundational pharmacokinetic study.